Linkedin
RLS logo_header
Linkedin

Boehringer Ingelheim and SBP Group enter partnership to advance next-generation cancer therapies

“Our second partnership with Boehringer Ingelheim marks an important milestone in SBP Group’s international innovation strategy and further validates our scientific capabilities in next-generation oncology. By combining our innovative platforms and early-development capabilities with Boehringer Ingelheim’s global oncology expertise, we aim to maximize the potential of these programs and bring innovative treatment options to patients worldwide. We will continue to expand our global partner network and contribute high-quality innovation from China to global healthcare,” said Theresa Tse, Chairwoman of SBP Group.

Read the full story on "Boehringer Ingelheim and SBP Group enter partnership to advance next-generation cancer therapies"

Share:

More News

Outcome from the End-of-Phase 1 Meeting with the FDA and Pivotal Ph 2 Trial Design for OMNI-EGFR™ Inhibitor, BH-30643, in EGFR C797S-Positive NSCLC Announced

“We are pleased with the outcome of our End-of-Phase 1 meeting with FDA and are confident in our development strategy for BH-30643 in EGFR C797S-positive NSCLC. Our planned Phase 2 trial, designed with registrational intent, builds on the encouraging clinical activity observed in SOLARA, where BH-30643 has demonstrated promising anti-tumor

Astellas and Audax Biosciences Enter Exclusive Option and License Agreement for DAX-044 for Immuno-Oncology

Jai Rautela, Ph.D., MBA, Chief Executive Officer, Audax Biosciences, “Astellas shares our pioneering spirit in immuno-oncology making them an ideal partner for highly differentiated programs such as DAX-044. This partnership will expedite the planned phase 1 clinical evaluation of DAX-044 for the benefit of patients with various types of solid

Updated Clinical Data of Zocilurtatug Pelitecan (Zoci) in Previously Treated Extrapulmonary Neuroendocrine Carcinomas Presented

“We are increasingly excited about the potential of zoci to provide an important new targeted therapeutic option for patients with multiple cancer types that commonly express DLL3, including epNECs,” said Rafael G. Amado, M.D., President, Head of Global Research and Development at Zai Lab. “We are pleased that results from

IND Clearance for KT-300 in for RAS-Driven Cancers Announced

“FDA clearance of the IND for KT-300, a potential first-in-class TRIM7 inhibitor, is an important milestone for Kayak and brings our novel approach to RAS-driven cancers into the clinic,” said Josiah Hornblower, CEO of Kayak Therapeutics. “TRIM7 sits at a critical downstream node of the RTK–RAS signaling cascade, and its